associated

OMNIA Protocol Integrates Blockpass to Secure DeFi Trading

Source Node:
Time Stamp: April 2, 2024 12:12 PM - Modified On: April 2, 2024 - Published By:
Source Cluster:
Republished By Plato

HONG KONG, Apr 2, 2024 - (ACN Newswire) - Blockpass is pleased to reveal a new partnership as OMNIA Protocol, a specialized RPC provider for DeFi traders, integrates Blockpass’ regulatory regulatory solutions. Through this integration, OMNIA benefits from compliance measures that include KYC, AML and KYB that will protect its users as they utilize the benefits of DeFi and the crypto space. Created by cybersecurity, privacy and trading experts, OMNIA aims to tackle DeFi issues including front-running and MEV exploitation to create an ecosystem where anyone can enjoy an unparalleled

Short Trading: A comprehensive analysis of the controversial strategy and an in-depth analysis of how investors make money from market declines

Source Node:
Time Stamp: March 19, 2024 8:45 AM - Modified On: March 19, 2024 - Published By:
Source Cluster:
Republished By Plato

Short trading is a strategy in which investors make money by taking advantage of predictions that a stock or other asset is expected to fall. The process involves borrowing shares and selling them immediately in the hope of buying them back at a lower price once their price drops, profiting from the difference between the selling and buying prices. Simply put, short trading is a way for investors to make profits through expected negative changes in the market. The Historical Origins of Short Trading The idea of ​​short trading can

A New Era of Ownership

Source Node:
Time Stamp: March 12, 2024 6:15 AM - Modified On: March 12, 2024 - Published By:
Source Cluster:
Republished By Plato

Months ago, the mainstream media wrote articles about how crypto was dead and that there would never be another bull run. Wild predictions of Bitcoin going to zero sought to instill fear in people so they would turn away from the markets and invest in more traditional assets. Yet, despite the doomsday prophecies, Bitcoin has surged to new heights, defying expectations even before the halving takes place. The media has quickly forgotten its failed predictions and instead turned its attention to the NFT market, echoing similar skepticism. Several articles have

AYA and Blockpass Collaborate to Ensure Compliance and Security in a Green Tech Future

Source Node:
Time Stamp: March 6, 2024 4:41 AM - Modified On: March 6, 2024 - Published By:
Source Cluster:
Republished By Plato

HONG KONG, Mar 6, 2024 - (ACN Newswire) - Blockpass is excited to announce a partnership with AYA, a regulated UAE-based fundraising platform focused on the intersection of blockchain and sustainability. Concerned with facilitating innovative solutions which encourage a greener future, AYA mentors and cultivates projects which combine the borderless, transparent nature of blockchain to further the goal of sustainablility and achieving the SDGs. This partnership will see Blockpass strengthening AYA's compliance procedures and providing: risk assessment and risk classification of onboarding customers, customized forms based on the customer's and

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Source Node:
Time Stamp: February 2, 2024 2:30 PM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

  New York, Feb 2, 2024 - (Plato Data)- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang. Avenue Therapeutics Finalizes Phase 3 Study for IV Tramadol with FDA Avenue Therapeutics, a subsidiary of Fortress Bio, has reached a significant milestone in its quest to introduce new therapies for neurologic diseases. The company

A Note On Charity Through Marginal Price Discrimination

Source Node:
Time Stamp: February 2, 2024 11:16 AM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

Vitalik Buterin via the Vitalik Buterin Blog Updated 2018-07-28. See end note. The following is an interesting idea that I had two years ago that I personally believe has promise and could be easily implemented in the context of a blockchain ecosystem, though if desired it could certainly also be implemented with more traditional technologies (blockchains would help get the scheme network effects by putting the core logic on a more neutral platform). Suppose that you are a restaurant selling sandwiches, and you ordinarily sell sandwiches for $7.50. Why did

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo

Source Node:
Time Stamp: October 5, 2023 11:22 AM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo Clinical trials, the linchpin of medical research, have long been riddled with inefficiencies, from patient recruitment bottlenecks to data management hurdles. As a technology and banking analyst, I've seen how digital solutions can overhaul entire sectors, offering improved productivity and streamlined processes. It's high time that clinical trials get a dose of such digital innovation, and there's a potent combination on the horizon: digital watermarking coupled with Artificial Intelligence (AI). At first glance, one might wonder: how can a technique often

Zilliqa partners with GMEX ZERO13 to launch consumer-focused carbon offset platform

Source Node:
Time Stamp: September 27, 2023 6:42 AM - Modified On: September 27, 2023 - Published By:
Source Cluster:
Republished By Plato

  LONDON, 27 September 2023 – Zilliqa, a leading layer-1 blockchain offering high-performance, high-security and low-fee solutions, today announces a partnership with GMEX Group and its initiative ZERO13, the digital climate fintech aggregation ecosystem, to launch the first-of-its-kind carbon offset platform that will transform the way that retail customers engage with corporate environmental initiatives. Together, Zilliqa Group and GMEX ZERO13 will deliver a cutting-edge platform that uses the blockchain-based currency, EVP, to represent carbon credit offsets. When they purchase goods or services, customers of brands partnered with Zilliqa will receive

Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications

Source Node:
Time Stamp: September 20, 2023 8:36 AM - Modified On: September 20, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionary AVERSA™ Technology Sets New Standard for Opioid Patch Safety ORLANDO, FL / September 20, 2023 - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance of a U.S. patent for its cutting-edge AVERSA™ Technology. This groundbreaking innovation, utilizing taste aversion, marks a paradigm shift in addressing the primary routes of abuse associated with opioid-based transdermal patches. The newly granted patent, numbered U.S. patent 11,759,431, titled "Abuse and Misuse Deterrent Transdermal Systems," significantly bolsters Nutriband's intellectual property protection in the United States. It covers